TRAW · Traws Pharma, Inc.
The AI's read
These findings strengthen the case for ratutrelvir as an option, especially for people unable to take PAXLOVID. The study also found fewer treatment-related problems and no viral rebound through Day 28. Traws also completed a tablet study and toxicology retesting for TXM, supporting a planned resubmission in Q4 2026. FDA discussions and further regulatory steps remain, so neither program's future use is assured.